Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia.

Abstract

Development and repurposing of therapies that show promise in the prevention or treatment of preeclampsia would be a major advance for the obstetrics field. We recently identified esomeprazole and sulfasalazine as potential candidates for the treatment of preeclampsia. Both reduce placental and endothelial secretion of sFlt-1 and sENG and mitigate endothelial dysfunction in vitro. Here we assessed whether esomeprazole and sulfasalazine in combination would additively attenuate the elevated release of anti-angiogenic factors and markers of endothelial dysfunction, key characteristics of preeclampsia. Primary placental tissue and cells, and primary endothelial cells were treated with esomeprazole and sulfasalazine alone and in combination. We assessed secretion of sFlt-1 and sENG and performed in vitro assays of endothelial dysfunction. Combining esomeprazole and sulfasalazine in lower concentrations caused an additive reduction in sFlt-1 secretion in primary cytotrophoblasts, placental explants and endothelial cells. No additive reduction was observed in sENG secretion when esomeprazole and sulfasalazine were combined. Together, esomeprazole and sulfasalazine additively reduced TNF-α-induced VCAM and ET-1 mRNA expression, and monocyte adhesion to endothelial cells. In conclusion, combining esomeprazole and sulfasalazine additively reduced secretion of sFlt-1 and markers of endothelial dysfunction. Combined administration of esomeprazole and sulfasalazine may provide a more effective treatment or prevention for preeclampsia compared to either as single agents.

• Authors: Natalie K Binder, Fiona C Brownfoot, Sally Beard, Ping Cannon, Tuong V Nguyen, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino, Natalie J Hannan
• Journal: Pregnancy hypertension (Pregnancy Hypertens) Vol. 22 Pg. 86-92 (Oct 2020) ISSN: 2210-7797 [Electronic] Netherlands
• PMID: 32758704 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Chemical References

• Sulfasalazine
• FLT1 protein, human
• Vascular Endothelial Growth Factor Receptor-1
• Esomeprazole

Topics

• Case-Control Studies
• Drug Therapy, Combination
• Esomeprazole (pharmacology)
• Female
• Human Umbilical Vein Endothelial Cells (drug effects)
• Humans
• Placenta (drug effects)
• Pre-Eclampsia (metabolism)
• Pregnancy
• Sulfasalazine (pharmacology)
• Vascular Endothelial Growth Factor Receptor-1 (drug effects)